Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
Simplified HCV Treatment* for Treatment-Naive Patients Without Cirrhosis
Four Indian generic companies take sub license from MPP on daclatasvir
Strategies to Secure Access to Generic HCV Medicines
2018 IAS Brief Document Ending an Epidemic – Prioritizing People Who Inject Drugs in HCV elimination Efforts.
Pricing of Indian generic sofosbuvir, 30th Jan,2016
A two pager of what you need to know of Sofosbuvir